Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of nimotuzumab plus paclitaxel as second-line treatment for EGFR-high recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20232230Phase 3Active
- Sponsor
- Biotech Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Nimotuzumab + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: overall survival. Started Aug 2024; status: active.
02
Drugs
nimotuzumabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20232230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232230.